Literature DB >> 26236802

Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain.

Shin-Ichi Miyatake, Noasuke Nonoguchi, Motomasa Furuse, Erina Yoritsune, Tomo Miyata, Shinji Kawabata, Toshihiko Kuroiwa.   

Abstract

New radiation modalities have made it possible to prolong the survival of individuals with malignant brain tumors, but symptomatic radiation necrosis becomes a serious problem that can negatively affect a patient’s quality of life through severe and lifelong effects. Here we review the relevant literature and introduce our original concept of the pathophysiology of brain radiation necrosis following the treatment of brain, head, and neck tumors. Regarding the pathophysiology of radiation necrosis, we introduce two major hypotheses: glial cell damage or vascular damage. For the differential diagnosis of radiation necrosis and tumor recurrence, we focus on the role of positron emission tomography. Finally, in accord with our hypothesis regarding the pathophysiology, we describe the promising effects of the anti-vascular endothelial growth factor antibody bevacizumab on symptomatic radiation necrosis in the brain.

Entities:  

Year:  2015        PMID: 26236802

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  4 in total

Review 1.  Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes.

Authors:  Ephraim E Parent; Derek R Johnson; Tyler Gleason; Javier E Villanueva-Meyer
Journal:  Neurooncol Pract       Date:  2021-05-04

2.  Salvage craniotomy for treatment-refractory symptomatic cerebral radiation necrosis.

Authors:  Ashish H Shah; Anil K Mahavadi; Alexis Morell; Daniel G Eichberg; Evan Luther; Christopher A Sarkiss; Alexa Semonche; Michael E Ivan; Ricardo J Komotar
Journal:  Neurooncol Pract       Date:  2019-07-03

3.  Celecoxib Alleviates Radiation-Induced Brain Injury in Rats by Maintaining the Integrity of Blood-Brain Barrier.

Authors:  Xiaoting Xu; Hao Huang; Yu Tu; Jiaxing Sun; Yaozu Xiong; Chenying Ma; Songbing Qin; Wentao Hu; Juying Zhou
Journal:  Dose Response       Date:  2021-06-14       Impact factor: 2.658

4.  Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report.

Authors:  Hongqing Zhuang; Xiangkun Yuan; Dayong Sun; Jianliang Bian; Joe Y Chang; Zhiyong Yuan; Ping Wang
Journal:  Oncotarget       Date:  2016-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.